In The News

    • OCT 27 2016

    ONC201 in Clinical Trial of Triple-Negative Breast Cancer at University of Wisconsin

    The study, being conducted by Dr. Vince Cryns, will enroll 112 patients who will receive ONC201 in combination with either a normal or methionine restricted diet. Dr. Cryns has shown in preclinical studies that methionine restriction makes cells more susceptible to ONC201’s cancer killing effects. The full release from the University of Wisconsin can be

    • OCT 19 2016

    FDA Announces Orphan Grant Recipients, Including Oncoceutics

    The U.S. Food and Drug Administration today announced that it has awarded 21 new clinical trial research grants totaling more than $23 million over the next four years to boost the development of products for patients with rare diseases. These new grants were awarded to principal investigators from academia and industry with research spanning domestic

    • OCT 06 2016

    Oncoceutics GPCR Discovery Partner DiscoverX Highlights Imipridone Class

    DiscoverX, a leader in GPCR profiling and screening services, recently highlighted imipridones, Oncoceutics’ proprietary class of small molecules, discussing their ability to target GPCRs, and the role that can play in developing cancer therapeutics. The article can be read here.  

    • AUG 25 2016

    The Role of DRD2 in Cancer

    An article written by Oncoceutics highlighting the role of Dopamine Receptor D-2 (DRD2) in cancer was featured by Drug Discovery and Development, a leading life sciences industry publication. DRD2 is the binding target of Oncoceutics’ lead anti-cancer imipridone molecule ONC201. The article can be read here.